Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Sebastian Schneeweiss, Sc.D., M.D.

Co-Author

This page shows the publications co-authored by Sebastian Schneeweiss and Daniel Solomon.
Connection Strength

12.593
  1. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011 Jun 22; 305(24):2525-31.
    View in: PubMed
    Score: 0.535
  2. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010 Dec 13; 170(22):1968-76.
    View in: PubMed
    Score: 0.516
  3. Solomon DH, Rassen JA, Glynn RJ, Garneau K, Levin R, Lee J, Schneeweiss S. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med. 2010 Dec 13; 170(22):1979-86.
    View in: PubMed
    Score: 0.516
  4. Solomon DH, Love TJ, Canning C, Schneeweiss S. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis. 2010 Dec; 69(12):2114-7.
    View in: PubMed
    Score: 0.500
  5. Schneeweiss S, Glynn RJ, Avorn J, Mamdani M, Mogun H, Solomon DH. NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib. Pharmacoepidemiol Drug Saf. 2009 Dec; 18(12):1134-42.
    View in: PubMed
    Score: 0.480
  6. Solomon DH, Hochberg MC, Mogun H, Schneeweiss S. The relation between bisphosphonate use and non-union of fractures of the humerus in older adults. Osteoporos Int. 2009 Jun; 20(6):895-901.
    View in: PubMed
    Score: 0.444
  7. Solomon DH, Lunt M, Schneeweiss S. The risk of infection associated with tumor necrosis factor alpha antagonists: making sense of epidemiologic evidence. Arthritis Rheum. 2008 Apr; 58(4):919-28.
    View in: PubMed
    Score: 0.428
  8. Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007 Jun; 56(6):1754-64.
    View in: PubMed
    Score: 0.404
  9. Schneeweiss S, Robicsek A, Scranton R, Zuckerman D, Solomon DH. Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. J Clin Epidemiol. 2007 Apr; 60(4):397-409.
    View in: PubMed
    Score: 0.391
  10. Solomon DH, Avorn J, Katz JN, Weinblatt ME, Setoguchi S, Levin R, Schneeweiss S. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Dec; 54(12):3790-8.
    View in: PubMed
    Score: 0.390
  11. Schneeweiss S, Solomon DH. Not-so-surprising findings. CMAJ. 2006 Jul 18; 175(2):171-2; author reply 172.
    View in: PubMed
    Score: 0.380
  12. Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, Canning C, Schneeweiss S. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis. 2006 Dec; 65(12):1608-12.
    View in: PubMed
    Score: 0.378
  13. Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum. 2006 May; 54(5):1378-89.
    View in: PubMed
    Score: 0.375
  14. Schneeweiss S, Glynn RJ, Tsai EH, Avorn J, Solomon DH. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology. 2005 Jan; 16(1):17-24.
    View in: PubMed
    Score: 0.342
  15. Schneeweiss S, Glynn RJ, Avorn J, Solomon DH. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol. 2005 Jan; 58(1):98-102.
    View in: PubMed
    Score: 0.342
  16. Kim SC, Pawar A, Desai RJ, Solomon DH, Gale S, Bao M, Sarsour K, Schneeweiss S. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study. Semin Arthritis Rheum. 2019 10; 49(2):222-228.
    View in: PubMed
    Score: 0.228
  17. Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, Schneeweiss S. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. Semin Arthritis Rheum. 2018 12; 48(3):399-405.
    View in: PubMed
    Score: 0.214
  18. Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, Schneeweiss S. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. Arthritis Rheumatol. 2017 06; 69(6):1154-1164.
    View in: PubMed
    Score: 0.201
  19. Franklin JM, Schneeweiss S, Solomon DH. Assessment of Confounders in Comparative Effectiveness Studies From Secondary Databases. Am J Epidemiol. 2017 03 15; 185(6):474-478.
    View in: PubMed
    Score: 0.199
  20. Kim SC, Schneeweiss S, Liu J, Karlson EW, Katz JN, Feldman S, Solomon DH. Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Rheumatoid Arthritis: A Cohort Study. Arthritis Rheumatol. 2016 09; 68(9):2106-13.
    View in: PubMed
    Score: 0.192
  21. Kim SC, Schneeweiss S, Choudhry N, Liu J, Glynn RJ, Solomon DH. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am J Med. 2015 Jun; 128(6):653.e7-653.e16.
    View in: PubMed
    Score: 0.172
  22. Kim SC, Solomon DH, Liu J, Franklin JM, Glynn RJ, Schneeweiss S. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. Am J Med. 2015 May; 128(5):539.e7-17.
    View in: PubMed
    Score: 0.170
  23. Kim SC, Schneeweiss S, Glynn RJ, Doherty M, Goldfine AB, Solomon DH. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. Ann Rheum Dis. 2015 Nov; 74(11):1968-75.
    View in: PubMed
    Score: 0.164
  24. Kim SC, Glynn RJ, Giovannucci E, Hernández-Díaz S, Liu J, Feldman S, Karlson EW, Schneeweiss S, Solomon DH. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis. 2015 Jul; 74(7):1360-7.
    View in: PubMed
    Score: 0.162
  25. Kim SC, Schmidt BM, Franklin JM, Liu J, Solomon DH, Schneeweiss S. Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout. Arthritis Care Res (Hoboken). 2013 Dec; 65(12):2008-14.
    View in: PubMed
    Score: 0.158
  26. Kim SC, Schneeweiss S, Liu J, Solomon DH. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013 Oct; 65(10):1600-7.
    View in: PubMed
    Score: 0.157
  27. Kim SC, Gillet VG, Feldman S, Lii H, Toh S, Brown JS, Katz JN, Solomon DH, Schneeweiss S. Validation of claims-based algorithms for identification of high-grade cervical dysplasia and cervical cancer. Pharmacoepidemiol Drug Saf. 2013 Nov; 22(11):1239-44.
    View in: PubMed
    Score: 0.156
  28. Rassen JA, Shelat AA, Franklin JM, Glynn RJ, Solomon DH, Schneeweiss S. Matching by propensity score in cohort studies with three treatment groups. Epidemiology. 2013 May; 24(3):401-9.
    View in: PubMed
    Score: 0.152
  29. Schneeweiss S, Rassen JA, Glynn RJ, Myers J, Daniel GW, Singer J, Solomon DH, Kim S, Rothman KJ, Liu J, Avorn J. Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Med Res Methodol. 2012 Nov 26; 12:180.
    View in: PubMed
    Score: 0.148
  30. Kim SC, Schneeweiss S, Myers JA, Liu J, Solomon DH. No differences in cancer screening rates in patients with rheumatoid arthritis compared to the general population. Arthritis Rheum. 2012 Oct; 64(10):3076-82.
    View in: PubMed
    Score: 0.146
  31. Solomon DH, Mercer E, Woo SB, Avorn J, Schneeweiss S, Treister N. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. Osteoporos Int. 2013 Jan; 24(1):237-44.
    View in: PubMed
    Score: 0.143
  32. Kim SY, Schneeweiss S, Liu J, Solomon DH. Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study. J Bone Miner Res. 2012 Apr; 27(4):789-96.
    View in: PubMed
    Score: 0.141
  33. Rassen JA, Solomon DH, Glynn RJ, Schneeweiss S. Simultaneously assessing intended and unintended treatment effects of multiple treatment options: a pragmatic "matrix design". Pharmacoepidemiol Drug Saf. 2011 Jul; 20(7):675-83.
    View in: PubMed
    Score: 0.133
  34. Kim SY, Solomon DH, Liu J, Chang CL, Daniel GW, Schneeweiss S. Accuracy of identifying neutropenia diagnoses in outpatient claims data. Pharmacoepidemiol Drug Saf. 2011 Jul; 20(7):709-13.
    View in: PubMed
    Score: 0.133
  35. Kim SY, Schneeweiss S, Katz JN, Levin R, Solomon DH. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res. 2011 May; 26(5):993-1001.
    View in: PubMed
    Score: 0.132
  36. Kim SY, Schneeweiss S, Katz JN, Levin R, Solomon DH. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res. 2010 Nov 18.
    View in: PubMed
    Score: 0.128
  37. Kim SY, Schneeweiss S, Liu J, Daniel GW, Chang CL, Garneau K, Solomon DH. Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther. 2010; 12(4):R154.
    View in: PubMed
    Score: 0.126
  38. Rassen JA, Solomon DH, Curtis JR, Herrinton L, Schneeweiss S. Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics. Med Care. 2010 Jun; 48(6 Suppl):S83-9.
    View in: PubMed
    Score: 0.124
  39. Schneeweiss S, Patrick AR, Solomon DH, Mehta J, Dormuth C, Miller M, Lee JC, Wang PS. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. Arch Gen Psychiatry. 2010 May; 67(5):497-506.
    View in: PubMed
    Score: 0.124
  40. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009 Aug; 30(3):253-64.
    View in: PubMed
    Score: 0.115
  41. Ting G, Schneeweiss S, Scranton R, Katz JN, Weinblatt ME, Young M, Avorn J, Solomon DH. Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. Arthritis Res Ther. 2008; 10(4):R95.
    View in: PubMed
    Score: 0.110
  42. Solomon DH, Glynn RJ, Rothman KJ, Schneeweiss S, Setoguchi S, Mogun H, Avorn J, Stürmer T. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008 Aug 15; 59(8):1097-104.
    View in: PubMed
    Score: 0.110
  43. Setoguchi S, Schneeweiss S, Avorn J, Katz JN, Weinblatt ME, Levin R, Solomon DH. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J. 2008 Aug; 156(2):336-41.
    View in: PubMed
    Score: 0.109
  44. Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, Levin R, Solomon DH. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum. 2007 Aug 15; 57(6):928-34.
    View in: PubMed
    Score: 0.102
  45. Brookhart MA, Patrick AR, Schneeweiss S, Avorn J, Dormuth C, Shrank W, van Wijk BL, Cadarette SM, Canning CF, Solomon DH. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007 Apr 23; 167(8):847-52.
    View in: PubMed
    Score: 0.100
  46. Setoguchi S, Solomon DH, Glynn RJ, Cook EF, Levin R, Schneeweiss S. Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. Cancer Causes Control. 2007 Jun; 18(5):561-9.
    View in: PubMed
    Score: 0.100
  47. Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. Arthritis Rheum. 2006 Nov; 54(11):3390-8.
    View in: PubMed
    Score: 0.097
  48. Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook EF, Carney G, Schneeweiss S. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Sep; 54(9):2757-64.
    View in: PubMed
    Score: 0.096
  49. Fischer MA, Cheng H, Schneeweiss S, Avorn J, Solomon DH. Prior authorization policies for selective cyclooxygenase-2 inhibitors in Medicaid: a policy review. Med Care. 2006 Jul; 44(7):658-63.
    View in: PubMed
    Score: 0.095
  50. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. Instrumental variable analysis of secondary pharmacoepidemiologic data. Epidemiology. 2006 Jul; 17(4):373-4.
    View in: PubMed
    Score: 0.095
  51. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology. 2006 May; 17(3):268-75.
    View in: PubMed
    Score: 0.094
  52. Sato M, Schneeweiss S, Scranton R, Katz JN, Weinblatt ME, Avorn J, Ting G, Shadick NA, Solomon DH. The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28. Arthritis Res Ther. 2006; 8(3):R57.
    View in: PubMed
    Score: 0.093
  53. Kinjo M, Setoguchi S, Schneeweiss S, Solomon DH. Bone mineral density in subjects using central nervous system-active medications. Am J Med. 2005 Dec; 118(12):1414.
    View in: PubMed
    Score: 0.091
  54. Brookhart MA, Solomon DH, Wang P, Glynn RJ, Avorn J, Schneeweiss S. Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. J Clin Epidemiol. 2006 Jan; 59(1):18-25.
    View in: PubMed
    Score: 0.091
  55. Ting G, Schneeweiss S, Katz JN, Weinblatt ME, Cabral D, Scranton RE, Solomon DH. Performance of a rheumatoid arthritis records-based index of severity. J Rheumatol. 2005 Sep; 32(9):1679-87.
    View in: PubMed
    Score: 0.089
  56. Winkelmayer WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH. Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis. 2005 Aug; 46(2):225-32.
    View in: PubMed
    Score: 0.089
  57. Fischer MA, Schneeweiss S, Avorn J, Solomon DH. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med. 2004 Nov 18; 351(21):2187-94.
    View in: PubMed
    Score: 0.085
  58. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004 Jul; 148(1):99-104.
    View in: PubMed
    Score: 0.083
  59. Solomon DH, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension. 2004 Aug; 44(2):140-5.
    View in: PubMed
    Score: 0.082
  60. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004 May 04; 109(17):2068-73.
    View in: PubMed
    Score: 0.081
  61. Solomon DH, Schneeweiss S, Glynn RJ, Levin R, Avorn J. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med. 2003 Dec 15; 115(9):715-20.
    View in: PubMed
    Score: 0.079
  62. Pawar A, Desai RJ, Solomon DH, Santiago Ortiz AJ, Gale S, Bao M, Sarsour K, Schneeweiss S, Kim SC. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis. 2019 04; 78(4):456-464.
    View in: PubMed
    Score: 0.057
  63. Desai RJ, Solomon DH, Schneeweiss S, Danaei G, Liao KP, Kim SC. Tumor Necrosis Factor-a Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis. Epidemiology. 2016 May; 27(3):414-22.
    View in: PubMed
    Score: 0.047
  64. Choudhry NK, Fischer MA, Avorn JL, Lee JL, Schneeweiss S, Solomon DH, Berman C, Jan S, Lii J, Mahoney JJ, Shrank WH. The impact of reducing cardiovascular medication copayments on health spending and resource utilization. J Am Coll Cardiol. 2012 Oct 30; 60(18):1817-24.
    View in: PubMed
    Score: 0.037
  65. Choudhry NK, Fischer MA, Avorn J, Schneeweiss S, Solomon DH, Berman C, Jan S, Liu J, Lii J, Brookhart MA, Mahoney JJ, Shrank WH. At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff (Millwood). 2010 Nov; 29(11):1995-2001.
    View in: PubMed
    Score: 0.032
  66. Shrank WH, Patrick A, Gleason PP, Canning C, Walters C, Heaton AH, Jan S, Brookhart MA, Schneeweiss S, Solomon DH, Wolf MS, Avorn J, Choudhry NK. An evaluation of the relationship between the implementation of a newly designed prescription drug label at Target pharmacies and health outcomes. Med Care. 2009 Sep; 47(9):1031-5.
    View in: PubMed
    Score: 0.030
  67. Shrank WH, Gleason PP, Canning C, Walters C, Heaton AH, Jan S, Patrick A, Brookhart MA, Schneeweiss S, Solomon DH, Avorn J, Choudhry NK. Can improved prescription medication labeling influence adherence to chronic medications? An evaluation of the Target pharmacy label. J Gen Intern Med. 2009 May; 24(5):570-8.
    View in: PubMed
    Score: 0.028
  68. Shrank WH, Choudhry NK, Solomon DH, Snedden TM, Lee TH, Glynn RJ, Brown TV, Jolda C, Spetman M, Brookhart MA, Schneeweiss S, Avorn J. Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial. Am Heart J. 2009 Apr; 157(4):613-9.
    View in: PubMed
    Score: 0.028
  69. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005 Dec 01; 353(22):2335-41.
    View in: PubMed
    Score: 0.023
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.